Error loading player: No playable sources found

ORIC-944, a Potent and Selective Allosteric PRC2 Inhibitor, Mediates Antitumor Efficacy Through Distinct Mechanisms in Two Prostate Cancer Xenograft Models

Date
June 21, 2021

Speaker

Speaker Image for Aleksandr Pankov
ORIC Pharmaceuticals